Genistein versus ICI 182, 780: An ally or enemy in metastatic progression of prostate cancer

Prostate

Volumn 73, Issue 16, 2013, Pages 1747-1760

  Nakamura, Hisae ^a,b,d   Wang, Yuwei ^a   Xue, Hui ^a   Romanish, Mark T ^b   Mager, Dixie L ^b,c   Helgason, Cheryl D ^a,c   Wang, Yuzhuo ^a,c,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

estrogen receptor beta; ICI182,780; metallothionein; metastasis; prostate cancer

Indexed keywords

ESTROGEN RECEPTOR BETA; FULVESTRANT; GENISTEIN; METALLOTHIONEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CHROMOSOME 14; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; EXON; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR PROMOTION;

ESTROGEN RECEPTOR BETA; ICI182,780; METALLOTHIONEIN; METASTASIS; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; MALE; METALLOTHIONEIN; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886948921     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22712     Document Type: Article

References (59)

1. Rhodes L, Ding VD, Kemp RK, Khan MS, Nakhla AM, Pikounis B, Rosner W, Saunders HM, Feeney WP,. Estradiol causes a dose-dependent stimulation of prostate growth in castrated beagle dogs. Prostate 2000; 44: 8-18.
2. Noble RL,. Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res 1980; 40: 3547-3550.
3. Ho SM, Roy D,. Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats. Cancer Lett 1994; 84: 155-162.
4. Prins GS,. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 1992; 130: 3703-3714.
5. Bosland MC,. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000; 27: 39-66.
6. Hill P, Garbaczewski L, Walker AR,. Age, environmental factors, and prostatic cancer. Med Hypotheses 1984; 14: 29-39.
7. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD, Platz EA,. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 2007; 92: 2519-2525.
8. Ahmad N, Kumar R,. Steroid hormone receptors in cancer development: A target for cancer therapeutics. Cancer Lett 2011; 300: 1-9.
9. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD, Jameson JL,. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 2001; 276: 13615-13621.
10. Safe S,. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001; 62: 231-252.
11. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA,. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-5930.
12. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA,. Mechanisms of estrogen action. Physiol Rev 2001; 81: 1535-1565.
13. Pearce ST, Jordan VC,. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004; 50: 3-22.
14. Saji S, Hirose M, Toi M,. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 2005; 56 (Suppl 1): 21-26.
15. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O,. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998; 95: 15677-15682.
16. Carruba G,. Estrogens and mechanisms of prostate cancer progression. Ann N Y Acad Sci 2006; 1089: 201-217.
17. Couse JF, Curtis Hewitt S, Korach KS,. Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J Steroid Biochem Mol Biol 2000; 74: 287-296.
18. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M,. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000; 127: 4277-4291.
19. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS,. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: Studies with alphaERKO and betaERKO mice. Cancer Res 2001; 61: 6089-6097.
20. Antal MC, Krust A, Chambon P, Mark M,. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci USA 2008; 105: 2433-2438.
21. Weihua Z, Warner M, Gustafsson JA,. Estrogen receptor beta in the prostate. Mol Cell Endocrinol 2002; 193: 1-5.
22. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E,. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004; 64: 814-820.
23. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H,., Ho SM,. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 79-92.
24. Nakamura H, Wang Y, Kurita T, Adomat H, Cunha GR,. Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PLoS ONE 2011; 6: e20034.
25. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD,. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 535-546.
26. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW,. MicroRNAs associated with metastatic prostate cancer. PLoS ONE 2011; 6: e24950.
27. Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang Y, Wang R, Chung LW, Zhau HE,. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS ONE 2011; 6: e28670.
28. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW,. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005; 64: 149-159.
29. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ,. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005; 85: 1392-1404.
30. Ramsey TL, Risinger KE, Jernigan SC, Mattingly KA, Klinge CM,. Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner. Endocrinology 2004; 145: 149-160.
31. Romanish MT, Nakamura H, Lai CB, Wang Y, Mager DL,. A novel protein isoform of the multicopy human NAIP gene derives from intragenic Alu SINE promoters. PLoS ONE 2009; 4: e5761.
32. Yuan JS, Wang D, Stewart CN Jr., Statistical methods for efficiency adjusted real-time PCR quantification. Biotechnol J 2008; 3: 112-123.
33. Younes M, Honma N,. Estrogen receptor beta. Arch Pathol Lab Med 2011; 135: 63-66.
34. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM,. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998; 247: 75-78.
35. Poola I, Abraham J, Baldwin K, Saunders A, Bhatnagar R,. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: Cloning from human ovary and functional characterization. Endocrine 2005; 27: 227-238.
36. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232-240.
37. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
38. Huggins C, Hodges CV,. Studies on prostatic cancer-I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
39. Cook JC, Johnson L, O'Connor JC, Biegel LB, Krams CH, Frame SR, Hurtt ME,. Effects of dietary 17 beta-estradiol exposure on serum hormone concentrations and testicular parameters in male Crl:CD BR rats. Toxicol Sci 1998; 44: 155-168.
40. Cox RL, Crawford ED,. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991-1998.
41. Denis LJ, Griffiths K,. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18: 52-74.
42. Prins GS,. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 1992; 130: 2401-2412.
43. McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP,. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001; 142: 2458-2467.
44. Cowley SM, Hoare S, Mosselman S, Parker MG,. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997; 272: 19858-19862.
45. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S,. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem 1997; 272: 25832-25838.
46. Gougelet A, Mueller SO, Korach KS, Renoir JM,. Oestrogen receptors pathways to oestrogen responsive elements: The transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha. J Steroid Biochem Mol Biol 2007; 104: 110-122.
47. Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA, Katzenellenbogen BS,. Estrogen Receptors alpha and beta as determinants of gene expression: Influence of ligand, dose, and chromatin binding. Mol Endocrinol 2008; 22: 1032-1043.
48. Winge DR,. Copper coordination in metallothionein. Methods Enzymol 1991; 205: 458-469.
49. Harris H, Henderson R, Bhat R, Komm B,. Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-beta activity in SAOS-2 and LNCaPLN3 cells. Endocrinology 2001; 142: 645-652.
50. Cherian MG, Jayasurya A, Bay BH,. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-209.
51. Nartey NO, Banerjee D, Cherian MG,. Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of fetal human liver and kidney and its changes during development. Pathology 1987; 19: 233-238.
52. Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D,. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 2008; 27: 6679-6689.
53. Schmid KW, Ellis IO, Gee JM, Darke BM, Lees WE, Kay J, Cryer A, Stark JM, Hittmair A, Ofner D,. Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol 1993; 422: 153-159.
54. Goulding H, Jasani B, Pereira H, Reid A, Galea M, Bell JA, Elston CW, Robertson JF, Blamey RW, Nicholson RA, et al. Metallothionein expression in human breast cancer. Br J Cancer 1995; 72: 968-972.
55. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Tarkowski R, Spytkowska B, Matkowski R, Kornafel J,. Correlation of metallothionein expression with clinical progression of cancer in the oral cavity. Anticancer Res 2009; 29: 589-595.
56. Yamasaki M, Nomura T, Sato F, Mimata H,. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 2007; 18: 1145-1153.
57. Hua P, Tsai WJ, Kuo SM,. Estrogen response element-independent regulation of gene expression by genistein in intestinal cells. Biochim Biophys Acta 2003; 1627: 63-70.
58. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M,. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999; 18: 4608-4618.
59. Hu X, Shelver WH,. Docking studies of matrix metalloproteinase inhibitors: Zinc parameter optimization to improve the binding free energy prediction. J Mol Graph Model 2003; 22: 115-126.